Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Chinese Patent Office
Fuji
US Army
Medtronic
Johnson and Johnson
Argus Health
Deloitte

Generated: May 27, 2018

DrugPatentWatch Database Preview

Keryx Biopharms Company Profile

« Back to Dashboard

What is the competitive landscape for KERYX BIOPHARMS, and when can generic versions of KERYX BIOPHARMS drugs launch?

KERYX BIOPHARMS has one approved drug.

There are thirteen US patents protecting KERYX BIOPHARMS drugs.

There are ninety-seven patent family members on KERYX BIOPHARMS drugs in twenty-three countries.

Summary for Keryx Biopharms
International Patents:97
US Patents:13
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Keryx Biopharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes 8,338,642 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes 7,767,851 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes 9,757,416 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes 8,609,896 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Keryx Biopharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,750,715 Method of reversing, preventing, delaying or stabilizing soft tissue calcification ➤ Try a Free Trial
9,913,821 Ferric organic compounds, uses thereof and methods of making same ➤ Try a Free Trial
9,889,113 Method for reversing, preventing, delaying or stabilizing soft tissue calcification ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fuji
Federal Trade Commission
Teva
Deloitte
Julphar
Baxter
Citi
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.